

**Wills Eye Hospital Ophthalmology Review Course 2023**

**Saturday, March 4, 2023 — Wednesday, March 8, 2023**

*Marriott Old City (Philadelphia)*

**Conference Description:**

Course Director  
Ralph C. Eagle, Jr., MD

Dates  
March 4 – 8, 2023

Location   
Marriott Old City, Philadelphia, PA

This live in-person course is a comprehensive and intensive review of ophthalmology for practicing ophthalmologists and ophthalmology residents and fellows. Topics taught by our world-renowned faculty range from anatomy, corneal diseases, eyelid, glaucoma, imaging, immunology, neuro-ophthalmology, oncology, orbit, ocular pathology, pediatrics, pharmacology, physiology, optics and refraction, and retina.

**Guest Faculty**

David L. Guyton, MD, Professor of Ophthalmology,  
The Wilmer Ophthalmological Institute, Johns Hopkins University,  
Baltimore, Maryland

Kristina Irsch, PhD, Assistant Professor of Ophthalmology,  
The Wilmer Ophthalmological Institute, Johns Hopkins University,  
Baltimore, Maryland

Peter J. Savino, MD, Clinical Professor of Ophthalmology & Neurosciences, Shiley Eye Institute, UC San Diego Health

Hermann D. Schubert, MD, Professor of Clinical Ophthalmology  
and Pathology, Columbia University, New York, New York  
  
**Wills Eye Hospital Faculty**

Jurij R. Bilyk, MD, Attending Surgeon, Oculoplastic Service

Jacqueline Carrasco, MD, Attending Surgeon, Oculoplastic & Orbital Surgery

Ralph C. Eagle, Jr., MD, Service Chief, Department of Pathology

Mitchell S. Fineman, MD, Attending Surgeon, Retina Service

Sunir J. Garg, MD, Attending Surgeon, Retina Service

Kristin M. Hammersmith, MD, Attending Surgeon, Cornea Service

Daniel Lee, MD, Attending Surgeon, Glaucoma Service

Jonathan S. Myers, MD, Service Chief, Glaucoma Service

Christopher J. Rapuano, MD, Service Chief, Cornea Service

Bruce M. Schnall, MD, Attending Surgeon, Adult and Pediatric Strabismus

Carol L. Shields, MD, Service Chief, Oncology Service

James F. Vander, MD, Attending Surgeon, Retina Service

Barry N. Wasserman, MD, Attending Surgeon, Pediatric Ophthalmology Service

This activity has been approved for AMA PRA Category 1 Credit™

**At the conclusion of the course, participants should be able to:**

1 Provide a comprehensive review of topics in ophthalmology including: Optics and Refraction; Antomy and Embryology; Retina and Vitreous; Ocular Pathology; Orbit, Eyelid and Lacrimal System; Pharmacology and Therapeutics; Ocular Tumors; Neuro-Ophthalmology; Corneal and External Diseases; Uveitis and AIDS; Glaucoma; Pediatric Ophthalmology and Strabismus; CT and MRI Imaging of Eye and Orbit.

2 Better understand the pathophysiology of most ophthalmic disease.

3 Perform appropriate diagnostic tests and differential diagnosis for most ophthalmic diseases.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this 45.50 for a maximum of 45.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**MOC Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning, Self-Assessment, Improvement in Medical Practice and/or Patient Safety requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| Ethan C Heck, MD | Activity Coordinator | Nothing to disclose - 11/03/2022 |
| Shaunna Lee, MD | Activity Coordinator | Nothing to disclose - 10/12/2022 |
| Jurij R. Bilyk, MD | Faculty | Nothing to disclose - 02/09/2023 |
| Jackie R. Carrasco, MD | Faculty | Speakers Bureau-Horizon Therapeutics - 11/03/2022 |
| Mitchell S. Fineman, MD | Faculty | Nothing to disclose - 02/05/2023 |
| Sunir J. Garg, MD | Faculty | Consulting Fee-Bausch + Lomb|Consulting Fee-Johnson & Johnson|Consulting Fee-Allergan|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Merck|Grant or research support-Allergan|Grant or research support-Boehringer Ingelheim|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Apellis Pharmaceuticals|Grant or research support-NGM Bio - 12/03/2022 |
| David L. Guyton, MD | Faculty | Grant or research support-Rebion, Inc (STTR grant from NIH) - 02/06/2023 |
| Kristin M. Hammersmith, MD | Faculty | Nothing to disclose - 10/27/2022 |
| Kristina Irsch, PhD | Faculty | Nothing to disclose - 02/08/2023 |
| Daniel Lee, MD | Faculty | Grant or research support-Allergan|Grant or research support-Equinox (Relationship has ended)|Grant or research support-Glaukos Corporation (Relationship has ended)|Grant or research support-Mati (Relationship has ended)|Grant or research support-New World Medical (Relationship has ended)|Grant or research support-Nicox (Relationship has ended)|Grant or research support-Olleyes|Consulting Fee-Quidel (Relationship has ended)|Grant or research support-Santen Pharmaceuticals (Relationship has ended) - 02/02/2023 |
| Jonathan S. Myers, MD | Faculty | Consulting Fee-Aerie Pharmaceuticals (Relationship has ended)|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Glaukos Corporation (Relationship has ended)|Grant or research support-Allergan|Grant or research support-Equinox|Grant or research support-Glaukos Corporation|Grant or research support-Nicox|Grant or research support-Santen Pharmaceuticals|Grant or research support-Guardian|Grant or research support-Haag Streit (Relationship has ended)|Consulting Fee-EmbarkNeuro|Grant or research support-Laboratories Thea Inc - 11/13/2022 |
| Christopher J. Rapuano, MD | Faculty | Consulting Fee-Bio-Tissue|Consulting Fee-Dompé |Consulting Fee-Glaukos Corporation|Consulting Fee-Oyster Point Pharmaceuticals|Consulting Fee-Sight Sciences|Consulting Fee-TearLab|Honoraria-Dompé  - 12/06/2022 |
| Peter J Savino, MD | Faculty | Nothing to disclose - 02/01/2023 |
| Bruce M. Schnall, MD | Faculty | Nothing to disclose - 01/07/2023 |
| Hermann D. Schubert, MD | Faculty | Nothing to disclose - 02/01/2023 |
| Carol L. Shields, MD | Faculty | Nothing to disclose - 02/01/2023 |
| James F. Vander, MD | Faculty | Nothing to disclose - 02/13/2023 |
| Barry N. Wasserman, MD | Faculty | Nothing to disclose - 11/20/2022 |
| Ralph C. Eagle Jr., MD | Faculty, Other Planning Committee Member | Nothing to disclose - 06/07/2022 |

